Abstract:Objective For major depressive disorder (MDD), there has been a lack of neuroimaging markers of efficacy of pharmacological treatment. In this study, we aimed to explore the neuroimaging mechanisms in patients with first-episode MDD and identify markers that predict the efficacy of 5-hydroxytryptamine reuptake inhibitors (SSRIs) with the use of resting-state brain imaging technology. Methods A total of 101 patients with first-episode MDD and 53 normal controls were finally included in this study. Based on the reduction rate of the score of Hamilton Depression Rating Scale (HAMD-17) during the 2-week SSRI treatment, 31 patients were assigned into the unresponsive group and 32 were assigned into the responsive group. The brain function was compared between patients with MDD and normal controls, and the diagnostic value of brain function was analyzed. With brain regions showing differences between patients with MDD and normal controls as a mask, and the brain function between the responsive and unresponsive groups were compared. Correlations between brain function the HAMD-17 score reduction rate during the 2-week SSRI treatment were analyzed. Results Compared to normal controls, patients with MDD showed increased ReHo in the left parahippocampal gyrus and right parahippocampal gyrus, decreased ReHo in the right middle occipital gyrus, and decreased functional connectivity between the right and left parahippocampal gyri, right middle occipital gyrus and middle temporal gyrus. Receiver operator characteristic (ROC) curve analysis showed that the area under the curve (AUC) was 0.544 (95% CI: 0.445–0.644) for ReHo and 0.822 (95% CI: 0.734–0.909) for functional connectivity. Logistic regression pooling of the differences in ReHo mean time series with the functional connectivity mean time series was performed for the ROC curve analysis, which showed an AUC of 0.832 (95% CI: 0.752–0.911). Compared to the responsive group, the unresponsive group showed elevated ReHo in the right parahippocampal gyrus and lower functional connectivity in the middle temporal gyrus. We also found that the ReHo value was negatively correlated with the HAMD-17 score reduction after 2 weeks of SSRI treatment. Conclusion Altered resting-state brain function in some regions might be a neurobiological marker for the diagnosis of MDD, and ReHo values are expected to be predictors of patient response to treatment with SSRIs. Clinical Trial Registration [ http://www.chictr.org.cn/ ], identifier [ChiCTR1900028722].

Short-term Effects of Escitalopram on Regional Brain Function in First-Episode Drug-Naive Patients with Major Depressive Disorder Assessed by Resting-State Functional Magnetic Resonance Imaging

565 – Abnormality of White Matter Structure and Resting State Brain Function in First-Episode, Treatment-Naive Patients with Major Depressive Disorder

Differential Effects of Antidepressant Treatment on Long-Range and Short-Range Functional Connectivity Strength in Patients with Major Depressive Disorder

The effects of antidepressant treatment on resting-state functional brain networks in patients with major depressive disorder.

Mapping the effect of escitalopram treatment on amplitude of low-frequency fluctuations in patients with depression: a resting-state fMRI study

Effects of escitalopram therapy on effective connectivity among core brain networks in major depressive disorder

Effects of 12‐week escitalopram treatment on resting‐state functional connectivity of large‐scale brain networks in major depressive disorder

Short-term Effects of Antipsychotic Treatment on Cerebral Function in Drug-Naive First-Episode Schizophrenia Revealed by “resting State” Functional Magnetic Resonance Imaging

Effect of short-term escitalopram treatment on neural activation during emotional processing

Resting-State fMRI in Predicting Response to Treatment With SSRIs in First-Episode, Drug-Naive Patients With Major Depressive Disorder

Resting state functional connectivity patterns as biomarkers of treatment response to escitalopram in patients with major depressive disorder

Dissociable Effects of Acute SSRI (escitalopram) on Executive, Learning and Emotional Functions in Healthy Humans.

Predicting Escitalopram Monotherapy Response in Depression: the Role of Anterior Cingulate Cortex

Eight-week Antidepressant Treatment Changes Intrinsic Functional Brain Topology in First-Episode Drug-Naïve Patients with Major Depressive Disorder

Vortioxetine Modulates the Regional Signal in First-Episode Drug-Free Major Depressive Disorder at Rest

Effects of escitalopram on synaptic density in the healthy human brain: a randomized controlled trial

Transcutaneous electrical cranial-auricular acupoint stimulation versus escitalopram for modulating the brain activity in mild to moderate major depressive disorder:an fMRI Study

Amygdala activity after subchronic escitalopram administration in healthy volunteers: A pharmaco-functional magnetic resonance imaging study

Spatio-temporal Dynamics of EEG Features During Sleep in Major Depressive Disorder after Treatment with Escitalopram: a Pilot Study

Spatio-temporal dynamics of EEG features during sleep in major depressive disorder after treatment with escitalopram:A pilot study

Short-term Effects of Risperidone Monotherapy on Spontaneous Brain Activity in First-episode Treatment-naïve Schizophrenia Patients: A Longitudinal Fmri Study